June 14, 2024

Best Health Ideas

Every Health & Fitness Helps

Can digital therapeutics become profitable?

This audio is auto-generated. Please let us know if you have feedback.

In 2020, the Food and Drug Administration cleared Akili Interactive’s video game to improve attention in kids with ADHD. It was the first time that a video game for treatment was cleared by the agency, and is one example of a digital therapeutic, a class of software-based treatments with FDA indications. 

Now, as the market is further developing, these companies have built up big ambitions.

Corey McCann, the CEO of Pear Therapeutics, which has three FDA-cleared digital treatments, hopes to make them the standard of care and garner widespread insurance coverage. After going public last year, Pear aims to increase its revenue 30-fold by 2023, based on expectations that more insurers will cover its products, and more physicians will write prescriptions. 

However, it remains to be seen whether they will be able to achieve these goals, or sustain the costs that come with developing a new class of treatments.

While getting FDA clearance was a first step, experts identified several hurdles ahead, including getting physician uptake, building pathways to reimbursement, and importantly, developing software that patients will want to use. 

“There’s still a lot of foundational work that needs to be done,” said Maya Desai,  director of life sciences for Guidehouse. “There’s a lot of behavioral change that needs to happen across the stakeholders and their mindsets to think about digital therapeutics as a category of its own.” 

Differentiating from wellness apps

One early challenge has been distinguishing digital therapeutics from other software products.

In a market saturated with hundreds of thousands of health and wellness apps, many of which are clamoring for benefits executives’ attention, companies that have garnered clinical evidence are looking to set themselves apart. Some, such as Pear, have started referring to their products as “prescription digital therapeutics,” or PDTs. 

There’s also substantial overlap, as many digital therapeutics are focused on behavioral health, which has also been a top area of investment among digital health companies. A few companies are considering other modalities, such as Voluntis, which got FDA clearance in 2019 for its software to help cancer patients manage their symptoms, and AppliedVR, which got FDA clearance last year for virtual reality-based cognitive behavioral therapy to treat chronic lower back pain.

 

Examples of digital therapeutics
Company Products
Pear Therapeutics Three FDA-cleared software products: reSET to treat substance use disorder, reSET-O to treat opioid use disorder, and Somryst for insomnia
Akili Interactive EndeavorRx, an FDA-cleared game to improve attention in kids with ADHD
Big Health Sleepio for insomnia and Daylight for anxiety. They are CE-marked but are not FDA cleared.
Voluntis Two FDA-cleared apps: Oleena, to help patients manage cancer symptoms, and Insulia, help with insulin dose titration for Type 2 diabetes
AppliedVR RelieVRx, an FDA-cleared virtual reality software to treat chronic lower back pain
Freespira Freespira, an FDA-cleared therapeutic to reduce panic symptoms through guided breathing exercises and a respiration rate sensor

Source: The Digital Therapeutics Alliance

Price is another area where prescription products differ from their over-the-counter counterparts. For instance, the average price for Akili’s game-based treatment, EndeavorRx, is $247 in cash, and $387 when reimbursed, according to an investor presentationAt launch, Pear’s app for insomnia was priced at $899, though it advertised a discount for new patients.

“We’re asking physicians to prescribe it. We’re asking patients to use a therapeutic versus just taking a pill…” Desai said. “Adhering to [digital therapeutics] long term, and even seeing the benefits, especially when we have a crowded market of wellness apps out there which tackle a lot of the therapeutic areas that companies are looking at, that requires a shift in mindset.”  

Andy Molnar, CEO of the Digital Therapeutics Alliance, said that initially, the rigor that went into proving digital therapeutics were safe and effective was not appreciated.

When Molnar started in the field, people assumed digital therapeutics might be a companion product that comes for free with a medication. Now, the CEO said people are considering the economic value of these products, as they would with durable medical equipment or pharmacologics. 

Is the business sustainable?

So far, just two digital therapeutics companies have publicly disclosed their financials: Pear, which began trading on the Nasdaq in December after merging with a special purpose acquisition company (SPAC), and Akili, which has also filed for a SPAC merger. Their revenues, a fraction of their accumulated deficits, pose a question: will they be able to carve out this new market quickly enough to sustain their businesses? 

Both companies have seen revenue decline in the last three years, as they’ve brought in less from licensing deals. For instance, Akili brought in nearly $20 million in revenue in 2019, while in 2020 it brought in nearly $4 million, most of which was from an ongoing licensing agreement with Shionogi & Co. to commercialize its products in Taiwan and Japan. Pear brought in $32 million in revenue in 2019, most of which came from an agreement with Novartis’ Sandoz, which dissolved that year amid a leadership shuffle in the drugmaker’s generics business. Last year, the company brought in $4.2 million. 

Pear projects that its revenue will increase to $22 million in 2022, and $125 million in 2023, per an investor presentation. At the same time, the company is projecting a corresponding increase in the number of people with insurance coverage for the service, prescriptions written and fulfillment rates.

Pear’s projected financials
Year Revenue Prescriptions Covered lives Fulfillment rates
2021(expected) $4M 12,500 30M-40M 50%
2021 (actual) $4.2M 14,000 31.7M 51%
2022 $22M 50,000-60,000 100M-120M 50-65%
2023 $125M 150,000-190,000 200M-230M 75%

Source: Pear Therapeutics investor presentation, March 2022

“It looks like an aggressive goal, a big step up from where they were,” said Marie Thibault, managing director of medical technology and digital health equity research for BTIG. “It’s a bit hard to know how this sort of increase is going to unfold.” 

However, Thibault noted that the company did meet its expected $4 million in revenue for last year, and reaffirmed its guidance for 2022. 

“When reimbursement kicks in, and when you have more prescribers prescribing more regularly, refilling prescriptions, as all of this comes together, we do expect Pear’s revenue to step up meaningfully throughout the year,” Thibault said. 

BTIG and Pear have had an investment banking services client relationship in the past year, and BTIG has received compensation for providing investment banking services. The firm also expects to receive or seek compensation from Pear in the next three months. 

Source: Pear’s annual earnings reports

Most of Pear’s revenue in 2021 came from sales of its products, marking a departure from previous years. Pear’s McCann told MedTech Dive that is also the main driver behind Pear’s figures for 2021 to 2023. 

“It’s not to say that we won’t do licensing deals, there’s still deals that the company may contemplate there. But I think the big driver is really in the core business model,” the CEO said. 

Licensing deals with pharmaceutical companies were an early strategy for digital health companies, but not all of them have lasted.